Hikma Pharmaceuticals PLC Annual report 2010 notes to tHe ConsoLIdAted FInAnCIALstAtements Continued 5. exCePtIonAL Items And IntAnGIBLe AmortIsAtIon Exceptional items are disclosed separately in the statement of comprehensive income to assist in the understanding of the Groups underlying performance.
For the years ended 31 december 2010 2009 $000 $000 Acquisition related expenses 7,705 Gains on revaluation of previously held equity interests 7,176 Exceptional items 529 Intangible amortisation 7,401 7,449 Exceptional items and intangible amortisation 7,930 7,449 tax effect 3,666 1,531 Impact on profit for the year 4,264 5,918 Intangible amortisation comprises the amortisation on intangible assets other than software.
Acquisition related expenses relate to transaction costs incurred in acquiring Ibn Al Baytar, Al Dar Al Arabia and the Baxter Multi-Source injectables business in the USA which is in the process of completion.
These are included in the unallocated corporate expenses.
Gains on revaluation of previously held equity interests relate to gains arising from the remeasurement to fair value of the previously held equity interest in Ibn Al Baytar and Al Dar Al Arabia.
These are included within other operating expenses net.
Further details are set out in Note 39 Acquisition of subsidiaries.
ProFIt For tHe yeAr Profit for the year has been arrived at after charging crediting : For the years ended 31 december 2010 2009 $000 $000 net foreign exchange losses 6,309 1,783 research and development costs 23,608 16,843 Loss on disposal of property, plant and equipment 376 236 depreciation of property, plant and equipment 29,091 25,199 Amortisation of intangible assets including software 9,342 8,949 Inventories: Cost of inventories recognised as an expense 247,774 213,558 write-down of inventories 13,076 12,501 staff costs see note 7 168,957 156,274 Auditors remuneration see below 5,014 1,302 Gains on revaluation of previously held equity interests see note 39 7,176 90
